Mayzent vs. Ocrevus

• Are Mayzent and Ocrevus the Same Thing?
• What Are Possible Side Effects of Mayzent?
• What Are Possible Side Effects of Ocrevus?
• What Is Mayzent?
• What Is Ocrevus?
• What Drugs Interact with Mayzent?
• What Drugs Interact with Ocrevus?
• How Should Mayzent Be Taken?
• How Should Ocrevus Be Taken?

Mayzent (siponimod) and Ocrevus (ocrelizumab) are used to treat relapsing forms of multiple sclerosis (MS).

Ocrevus is also used to treat primary progressive forms of multiple sclerosis.

Mayzent and Ocrevus belong to different drug classes. Mayzent is a sphingosine 1-phosphate receptor modulator and Ocrevus is a CD20-directed cytolytic antibody.

Side effects of Mayzent and Ocrevus that are similar include pain and swelling in extremities.

Side effects of Mayzent that are different from Ocrevus include headache, high blood pressure (hypertension), increased liver transaminase, falls, nausea, dizziness, diarrhea, and slow heart rate.

Side effects of Ocrevus that are different from Mayzent include upper or lower respiratory tract infections, infusion reactions (itching, rash, hives, redness, bronchospasm, swollen and sore throat, mouth pain, shortness of breath, flushing, hypotension, fever, fatigue, headache, dizziness, nausea, and fast heart rate), skin infections, depression, and back pain.

Both Mayzent and Ocrevus may interact with immune-modulating drugs and immunosuppressive therapies.

Mayzent may also interact with "live" vaccines, cancer medications, anti-arrhythmics, QT prolonging drugs, calcium channel blockers, other drugs that may decrease heart rate, beta-blockers, fluconazole, rifampin, carbamazepine, modafinil, and efavirenz.

Common side effects of Mayzent include:

• headache,
• high blood pressure (hypertension),
• increased transaminase,
• falls,
• swelling of extremities,
• nausea,
• dizziness,
• diarrhea,
• slow heart rate, and
• pain in extremities

Common side effects of Ocrevus include:

• upper respiratory tract infections,
• infusion reactions (itching, rash, hives, redness, bronchospasm, swollen and sore throat, mouth pain, shortness of breath, flushing, hypotension, fever, fatigue, headache, dizziness, nausea, and fast heart rate),
• skin infections,
• lower respiratory tract infections,
• depression,
• back pain, and
• pain in the extremities.

Mayzent (siponimod) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Ocrevus (ocrelizumab) injection is aCD20-directed cytolytic antibody indicated for the treatment of patients with relapsing or primary progressive forms of multiple sclerosis.

Mayzent may interact with:

• "live" vaccines,
• cancer medications,
• immune-modulating drugs,
• immunosuppressive therapies,
• anti-arrhythmics,
• QT prolonging drugs,
• calcium channel blockers,
• other drugs that may decrease heart rate,
• beta-blockers,
• fluconazole,
• rifampin,
• carbamazepine,
• modafinil, or
• efavirenz.

Hepatitis B virus screening is required before the first dose of Ocrevus. Pre-medicate with methylprednisolone (or an equivalent corticosteroid) and an antihistamine prior to each infusion. The starting dose of Ocrevus is 300 mg intravenous infusion, followed two weeks later by a second 300 mg intravenous infusion. Subsequent doses of Ocrevus are 600 mg intravenous infusion every 6 months.

Initiate Mayzent with a 5-day titration. The recommended maintenance dosage of Mayzent is 2 mg.

The recommended dosage of Ocrevus is 12 mg/day administered by intravenous infusion for 2 treatment courses: First Treatment Course: 12 mg/day on 5 consecutive days (60 mg total dose; Second Treatment Course: 12 mg/day on 3 consecutive days (36 mg total dose) administered 12 months after the first treatment course.